Haesook Kim

Senior Research Scientist
This email address is being protected from spambots. You need JavaScript enabled to view it.



Our major research activities involve the design, conduct and analysis of translational clinical trials, animal and laboratory studies that arise from adult hematopoietic stem cell transplantation (HSCT) projects and cancer vaccine studies at DF/HCC, as well as translational laboratory studies of leukemia outside of DF/HCC. Our major statistical interests include the design of clinical trials, analysis of competing risks data, analysis of time-to-event data, analysis of longitudinal data, and analysis of SNP and gene array data.

Allogeneic hematopoietic stem cell transplantation (HSCT) is the transplantation of stem cells derived from the bone marrow or blood. The therapeutic benefit and potential cure achieved by HSCT is mediated by the graft-vs-tumor effect. The conventional HSCT has used high doses of chemotherapy and/or total body irradiation for both eradication of underlying malignancies and suppression of the host's immune system to allow donor engraftment. However, the conventional HSCT has an impact on the increased tissue damage and intensified inflammatory state in the host, leading to significant transplant-related mortalities and morbidities. Reduced intensity conditioning regimens (RIC) use less intense conditioning regimens and rely on the adoptively transferred donor's immune cells for the eradication of host malignancies. Thus, RIC has opened the possibility of HSCT for the elderly and for patients with comorbid conditions who would otherwise be ineligible for conventional HSCT. Unfortunately, RIC is associated with an increased risk of disease recurrence, indicating that the immunologic effects of these two types of transplant on disease recurrence and transplant-related mortality are different.


Competing risks data are inherent in HSCT studies since the immunologic mechanisms of disease recurrence and transplant-related mortality are interdependent, and efforts have been made to reduce transplant related mortality (RIC) but at the cost of increased risk of disease recurrence. Thus, when competing risks are present, standard time-to-event analysis censoring competing risks leads to biased results. Instead, competing risks data analysis should be performed.



Dr. Kim received her PhD in 1994 from the University of North Carolina at Chapel Hill, and then worked for the National Institute of Child Health and Human Development. Later she was an Assistant professor at the University of Pittsburgh, and in 1999, joined DFCI, where she has served as a statistician for leukemia, allogeneic stem cell transplantation, cancer vaccine studies, and studies of human cell therapies. Her research focuses on statistical issues of designing clinical trials and analysis of competing risks data, time-to-event data, and SNP and gene array data with special emphasis on stem cell transplantation and cancer vaccine studies.


Recent Publications

Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, Murase K,Cutler C, Ho VT, Alyea EP, Armand P, Blazar BR, Antin JH, Soiffer RJ, Ritz J. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013 Apr 3;5(179):179ra43.


Nikiforow S, Kim HT, Bindra B, McDonough S, Glotzbecker B, Armand P, Koreth J, Ho VT, Alyea EP 3rd, Blazar BR, Ritz J, Soiffer RJ, Antin JH, Cutler CS. Phase I Study of Alemtuzumab for Therapy of Steroid-Refractory Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2013 May;19(5):804-11.


Rego EM, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte Mdel R, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Chauffaille Mde L, Chiattone CS, Martinez L, Meillón LA, Gómez-Almaguer D, Kwaan HC, Garcés-Eisele J, Gallagher R, Niemeyer CM, Schrier SL, Tallman M, Grimwade D, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Sanz MA. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood. 2013 Mar 14;121(11):1935-43.


Kim HT, Armand P. Clinical Endpoints in Allogeneic Hematopoietic Stem CellTransplantation Studies: The Cost of Freedom. Biol Blood Marrow Transplant. 2013 Jan 7. doi:pii: S1083-8791(13)00016-5.
10.1016/j.bbmt.2013.01.003. [Epub ahead of print]


Armand P, Welch S, Kim HT, LaCasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Coughlin E, Freedman AS, Chen YB. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol. 2013 Mar;160(5):608-17.


Koreth J, Stevenson KE, Kim HT, McDonough SM, Bindra B, Armand P, Ho VT, Cutler C, Blazar BR, Antin JH, Soiffer RJ, Ritz J, Alyea EP 3rd. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol. 2012 Sep 10;30(26):3202-8.


Wiernik PH, Sun Z, Gundacker H, Dewald G, Slovak ML, Paietta E, Kim HT,
Appelbaum FR, Cassileth PA, Tallman MS. Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17). Med Oncol. 2012 Sep;29(3):2095-101.


Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, Ritz J, Sorror ML, Lee SJ, Deeg HJ, Storer BE, Appelbaum FR, Antin JH, Soiffer RJ, Kim HT. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012 Jul 26;120(4):905-13.


Rego EM, Kim HT, Ruiz-Argüelles GJ, Uriarte Mdel R, Jacomo RH,
Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Chauffaille Mde L, Chiattone C, Martinez L, Meillón LA, Gómez-Almaguer D, Kwaan H, Garcés-Eisele J, Gallagher R, Niemeyer CM, Lowenberg B, Ribeiro R, LoCoco F, Sanz MA. The impact of medical education and networking on the outcome of leukemia treatment in developing countries. The experience of International Consortium on Acute Promyelocytic Leukemia (IC-APL). Hematology. 2012 Apr;17 Suppl 1:S36-8.


Armand P, Sainvil MM, Kim HT, Rhodes J, Cutler C, Ho VT, Koreth J, Alyea EP, Neufeld EJ, Kwong RY, Soiffer RJ, Antin JH. Does iron overload really matter in stem cell transplantation? Am J Hematol. 2012 Jun;87(6):569-72.


Related Links